4. As of noon trading, Celgene Corporation ( CELG) is up $3.99 (5.6%) to $75.49 on heavy volume Thus far, 5.1 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $74.30-$78.46 after having opened the day at $78.02 as compared to the previous trading day's close of $71.50. Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $30.2 billion and is part of the drugs industry. The company has a P/E ratio of 19.8, above the S&P 500 P/E ratio of 17.7. Shares are up 5.8% year to date as of the close of trading on Friday. Currently there are 19 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Celgene Corporation Ratings Report now.